IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
Rhea-AI Summary
IRADIMED (NASDAQ: IRMD) will release its Q1 2026 financial results before market open on May 1, 2026. Management will host a conference call the same day at 11:00 a.m. ET to discuss results and answer questions. Registration is required for dial-in details and a webcast will stream live; a recording will be posted after the call.
Positive
- None.
Negative
- None.
News Market Reaction – IRMD
In the Apr 27 session, IRMD gained 0.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Earnings call schedule | Neutral | +0.7% | Announcement of Q4 and full‑year 2025 results release and conference call. |
| Oct 27 | Earnings call schedule | Neutral | +2.6% | Set Q3 2025 results release date and related investor conference call. |
| Jul 25 | Earnings call schedule | Neutral | +1.4% | Scheduled Q2 2025 results release and 11:00 a.m. Eastern conference call. |
| Apr 28 | Earnings call correction | Neutral | -0.6% | Corrected details for Q1 2025 results release and call timing on May 5, 2025. |
| Apr 28 | Earnings call schedule | Neutral | -0.6% | Initial announcement of Q1 2025 results release and conference call schedule. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings conference‑call scheduling headlines have historically led to modest single‑day moves in both directions, suggesting limited standalone impact.
This announcement continues IRADIMED’s pattern of pre‑announcing quarterly results and hosting calls at 11:00 a.m. Eastern Time. Prior “conferences,earnings” notices for Q1–Q4 2025 around dates like May 5, 2025 and February 10, 2026 produced small price reactions between about -0.56% and 2.65%. Against that backdrop, the new Q1 2026 call date on May 1, 2026 fits an established communications cadence rather than marking a new strategic shift.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
